Prasugrel vs. Clopidogrel, Continued . . .

A subanalysis of TRITON-TIMI 38 suggests that prasugrel lowers stent thrombosis rates in high-risk ACS patients.

TRITON-TIMI 38 was a manufacturer-sponsored, randomized, double-blind comparison of clopidogrel and prasugrel in patients undergoing PCI for moderate- and high-risk acute coronary syndromes. The main findings, reported in November 2007 (Journal Watch Cardiology Nov 4 2007), confirmed old wisdom: An increase in the potency of platelet inhibition confers a higher bleeding risk. The current study is a subanalysis confined to the 12,844 patients with moderate- and high-risk ACS who received at least one stent (bare metal stents only, 6461; drug-eluting stents only, 5743; both types, 640); this group comprised 94% of the overall study population. Randomization was not stratified by use or type of stent.

Compared with clopidogrel recipients, prasu…

Reviewing Author

Beat J. Meyer, MD

Disclosures

Leadership positions in professional societiesBern Heart Foundation (President); International Academy of Medicine, Bern, Switzerland (Director)

Beat J. Meyer, MD

Disclosures

Leadership positions in professional societiesBern Heart Foundation (President); International Academy of Medicine, Bern, Switzerland (Director)

Prasugrel vs. Clopidogrel, Continued . . .

Topics

Reviewing Author